Becton, Dickinson and Company (NYSE:BDX) Plans Quarterly Dividend of $1.05

Becton, Dickinson and Company (NYSE:BDX) declared a quarterly dividend on Thursday, November 6th. Investors of record on Monday, December 8th will be given a dividend of 1.05 per share by the medical instruments supplier on Wednesday, December 31st. This represents a c) annualized dividend and a yield of 2.4%. The ex-dividend date of this dividend is Monday, December 8th. This is a 1.0% increase from Becton, Dickinson and Company’s previous quarterly dividend of $1.04.

Becton, Dickinson and Company has raised its dividend by an average of 0.0%per year over the last three years and has increased its dividend every year for the last 53 years. Becton, Dickinson and Company has a payout ratio of 28.3% meaning its dividend is sufficiently covered by earnings. Equities analysts expect Becton, Dickinson and Company to earn $15.64 per share next year, which means the company should continue to be able to cover its $4.16 annual dividend with an expected future payout ratio of 26.6%.

Becton, Dickinson and Company Price Performance

Becton, Dickinson and Company stock opened at $177.44 on Friday. The company has a fifty day simple moving average of $187.07 and a 200-day simple moving average of $182.55. The firm has a market capitalization of $50.86 billion, a price-to-earnings ratio of 31.91, a PEG ratio of 1.42 and a beta of 0.25. The company has a quick ratio of 0.62, a current ratio of 1.10 and a debt-to-equity ratio of 0.69. Becton, Dickinson and Company has a 52-week low of $162.29 and a 52-week high of $251.99.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings results on Thursday, April 14th. The medical instruments supplier reported $4.10 earnings per share for the quarter. Becton, Dickinson and Company had a net margin of 7.51% and a return on equity of 16.23%. The firm had revenue of $5.32 billion for the quarter. On average, equities analysts anticipate that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on BDX shares. Royal Bank Of Canada restated a “sector perform” rating and issued a $211.00 price target on shares of Becton, Dickinson and Company in a research report on Thursday, October 16th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Becton, Dickinson and Company in a research note on Wednesday, October 8th. Argus lifted their target price on Becton, Dickinson and Company from $220.00 to $230.00 in a research report on Monday, September 15th. Piper Sandler reduced their price target on Becton, Dickinson and Company from $200.00 to $190.00 and set a “neutral” rating on the stock in a research report on Friday. Finally, Wall Street Zen raised Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a report on Saturday, August 9th. Three analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $204.40.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.